Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Export-oriented generic pharmaceutical company focused on over-the-counter and prescription products for the US, UK/Europe and Australia, with strengths in soft-gelatin capsules and solid orals across pain management, cough & cold and gastro categories. Operates through subsidiaries including Time-Cap Labs (US) and Bell, Sons & Co. (UK), with manufacturing in Goa and overseas; store-brand/private-label OTC supply is a key revenue driver.
Marksans Pharma Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Marksans Pharma Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
Per-share figures are not restated. Shares outstanding changed from 45.32 crore to 4.53 crore in FY25, consistent with a bonus issue or stock split. Each year's EPS and book value below are as that year was filed, on that year's share count — so the per-share line falls across FY25 even where profit did not. Compare the absolute figures (EBITDA, free cash flow, total debt) and the margins across that boundary, not the per-share ones.
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 9.22 | 8.40 | 6.92 |
| Book value / share (₹) | 67.36 | 54.93 | 46.03 |
| Return on equity | 13.7% | 15.4% | 16.4% |
| Return on capital employed | 15.1% | 16.1% | 16.8% |
| Operating margin | 17.0% | 17.0% | 17.6% |
| Net margin | 14.2% | 14.6% | 14.5% |
| EBITDA | ₹601 Cr | ₹53 Cr | ₹459 Cr |
| Free cash flow | ₹328 Cr | ₹3 Cr | ₹22 Cr |
| Total debt | ₹30 Cr | ₹2 Cr | ₹29 Cr |
| Debt to equity | 0.01 | 0.01 | 0.01 |
| Interest coverage | 20.8 | 38.2 | 34.3 |
| Current ratio | 5.17 | 4.62 | 4.78 |
| Shares outstanding | 45,31,60,000 | 4,53,16,000 | 45,31,60,000 |
Open the full income statement, balance sheet and cash flow for MARKSANS →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.